Vorachai RatanatharathornVicharn LorvidhayaSavitree MaoleekoonpairojPramook PhromratanapongseSuwannee SirilerttrakulPuangthong KraipiboonArkom CheirsilpaSaipin TangkarattVichien SrimuninnimitPitayapoon PattaranutapornMahidol UniversityChiang Mai UniversityPramongkutklao HospitalNational Cancer Institute Thailand2018-09-072018-09-072001-02-10Lung Cancer. Vol.31, No.2-3 (2001), 257-265016950022-s2.0-0035139474https://repository.li.mahidol.ac.th/handle/20.500.14594/26846We conducted a phase II trial to investigate the efficacy of concurrent chemoradiation in patients with stage III non-small-cell lung cancer (NSCLC). Thirty patients with inoperable NSCLC were enrolled onto a multicenter phase II trial of concurrent chemoradiation therapy. Patients received six weekly cycles of paclitaxel 45 mg/m2over 1 h; carboplatin at (area under the curve) AUC 2; and radiation therapy of 60 Gy. Radiation was administered to the primary tumor and regional lymph nodes (40 Gy over 4 weeks) followed by a boost to the primary tumor (20 Gy in 2 weeks). After the initial phase of concurrent chemoradiation, patients received an additional four cycles of paclitaxel 175 mg/m2over 3 h and carboplatin at AUC 6 every 3 weeks. The overall objective response rate of 30 assessable patients was 76.7%. At the median follow-up time of 13.1 months, the median survival time was 14.5 months (95% CI, 10.59-18.48). The median progression-free survival was 10.5 months (95% CI, 7.72-13.28). The major toxicity was hematologic. The incidence of grade 3 esophagitis was 10%. In conclusion, this chemoradiation regimen is well tolerated and shows significant clinical results for locally advanced NSCLC. Locoregional failure rate remains an important issue with this newer chemotherapeutic regimen. A novel chemotherapy and radiation therapy is clearly needed. Copyright © 2001 Elsevier Science Ireland Ltd.Mahidol UniversityMedicineArticleSCOPUS10.1016/S0169-5002(00)00171-9